Genetic testing for mutations in the CDC73 (HRPT2) gene was negative; MEN‐1 mutations were not evaluated due to the absence of evidence of other associated tumors or familial history of hypercalcemia or MEN‐1‐associated tumors. This evidence concerns the gene CDC73 and hypercalcemia disease.